The aim of this study was to evaluate the effects of prostaglandin E 2 (PGE 2 ) on haematopoietic stem cell (HSC) function and determine its mechanism of action.
Introduction
Prostaglandins (PGs) are extremely active short-lived lipids that act locally in a paracrine or autocrine fashion. There are no organs, tissues or cells in the body that are not affected by these bioactive lipids, either directly or through accessory mechanisms. All nucleated cells synthesize PGs by cleavage of the essential fatty acid, arachidonic acid from membrane phospholipids by phospholipase A2, oxidation of free arachidonic acid by two cyclooxygenase enzymes (COX1 and COX2) and subsequent isomerization to an intermediate form, and synthesis of various mature PGs by specific synthases (2, 3) . A schematic outline of prostaglandin E 2 (PGE 2 ) biosynthesis is shown in Fig. 1 . PGE 2 is the predominant metabolite of arachidonic acid and is the most abundant eicosanoid (4, 5) . PGE 2 has been implicated in regulation of numerous physiological systems, and is the primary mediator of symptoms of fever (6) and inflammation (4, 7) , a regulator of atherosclerosis, blood pressure and strokes (7) , and is involved in neoplastic transformation and cancer cell effects on host responses (4, 8) . Effects of PGE 2 are mediated through four highly conserved G-protein-coupled receptors (EP1-4) with overlapping as well as distinct signalling pathways (9, 10) that can lead to seemingly opposing effects. EP receptor levels vary among tissues, and signalling pathways downstream of the same receptors can vary depending upon cell lineage.
Previously we have shown that PGE 2 regulates haematopoiesis, affecting both haematopoietic stem cell (HSC) and progenitor cell (HPC) functions. PGE 2 inhibits myelopoiesis in vitro and in vivo (11) (12) (13) , and participates in a negative feedback loop regulating myeloid progenitor cell expansion (12, 14, 15) . In contrast to its effects on myelopoiesis, PGE 2 promotes erythroid and multipotential colony formation in vitro (16, 17) . Early studies showed that short-term ex vivo treatment of bone marrow cells with PGE 2 could enhance progenitor cell proliferation (18, 19) ; however, in vivo dosing led to little or no effect (20) . We later showed that pulse exposure of mouse or human bone marrow cells to PGE 2 stimulated proliferation, cycling and differentiation of quiescent cells leading to an increase in cycling HPC, suggesting that PGE 2 enhances HSC function (21) (22) (23) . These studies also clearly defined that dose, timing and length of exposure of haematopoietic cells to PGE 2 were critical factors defining stimulatory versus inhibitory effects on haematopoiesis. However, while these studies were the first to clearly implicate PGE 2 in positive regulation of haematopoiesis, stem cell function cannot be defined solely based on clonogenic assays. Elucidation of the effects of PGE 2 on HSC function requires demonstration that transplanted cells can repopulate haematopoiesis in myeloablated hosts (24) . Recently, effects of PGE 2 on haematopoietic stem cell function have been revisited and studies in zebrafish and mice (25, 26) validate the stimulatory effects of PGE 2 on HSC function that were suggested in earlier in vitro studies. In addition, we have defined mechanisms of action of PGE 2 on HSC function, particularly on HSC homing and selfrenewal, which suggest that short-term exposure of haematopoietic grafts to PGE 2 can be utilized for therapeutic benefit in HSC transplantation (25) . In this study, we describe preclinical findings supporting the therapeutic ex vivo utility of PGE 2 as a facilitator of HSC engraftment.
Materials and methods

Mouse and human cord blood
C57Bl ⁄ 6 (CD45.2) mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). B6.SJL-PtrcA-Pep3B ⁄ BoyJ (BOYJ) (CD45.1), C57Bl ⁄ 6 X BOYJ-F1 (CD45.1 ⁄ CD45.2) and NOD.Cg-Prkdcscid IL2rgtm1Wjl ⁄ Sz (NSG) mice were bred in-house. Human umbilical cord blood (UCB) was obtained from Wishard Hospital, India-napolis, IN, with IRB approval.
Flow cytometry
For detection of SKL cells, streptavidin conjugated with PE-Cy7 [to stain for biotinylated MACS lineage antibodies (Miltenyi Biotech, Auburn, CA, USA)], c-kit-APC, Sca-1-PE or APC-Cy7, CD45.1-PE, CD45.2-FITC and CD34-PE were used (BD Biosciences, San Jose, CA, USA). For SLAM SKL, we used Sca-1-PE-Cy7, c-kit-FITC, CD150-APC (eBiosciences, San Diego, CA, USA), CD48-biotin (eBiosciences) and streptavidin-PE. UCB CD34 + cells were detected using anti-human-CD34-APC. For multi-lineage analysis, APC-Cy7-Mac-1, PE-Cy7-B-220 and APC-CD3 were used (BD Biosciences).
PGE 2 pulse exposure
Cells were incubated with 16,16-dimethyl prostaglandin E 2 (dmPGE 2 ) (Cayman Chemicals, Ann Arbor, MI, USA) (reconstituted in 100% ethanol) diluted in media, on ice, for 2 h. After incubation, cells were washed twice before use. Vehicle-treated cells were pulsed with equivalent concentration of ethanol.
Limiting dilution competitive and non-competitive transplantation
Whole bone marrow cells (CD45.2) were treated with 1 µM dmPGE 2 or 0.001% EtOH, washed, admixed with 2 × 10 5 congenic CD45.1 competitor marrow cells at various ratios, and transplanted into lethally irradiated CD45.1 ⁄ CD45.2 mice. Peripheral blood CD45.1 and CD45.2 cells were determined monthly by FACS. HSC frequency was quantified by Poisson statistics using L-CALC software (Stem Cell Technologies, Vancouver BC, Canada). Competitive repopulating units (CRU) were calculated as described by Harrison (24) . For secondary transplantation, 2 × 10 6 WBM from previously transplanted CD45.1 ⁄ CD45.2 mice at 20 weeks post-transplant were injected into lethally irradiated CD45.1 ⁄ CD45.2 mice in a non-competitive fashion.
HSPC homing
For competitive homing studies, SKL cells from CD45.2 and CD45.1 mice were FACS sorted, treated with dmPGE 2 or vehicle and 3 × 10 4 CD45.1 (vehicle or dmPGE 2 treated) plus 3 × 10 4 CD45.2 (dmPGE 2 or vehicle treated) SKL cells transplanted into lethally irradiated CD45.1 ⁄ CD45.2 mice. Homed CD45.1 and CD45.2 SKL cells in bone marrow were determined after 16 h. To evaluate the role of CXCR4 in homing, Lin neg CD45.2 cells were treated with vehicle or 1 µM dmPGE 2 plus 10 µM AMD3100 (AnorMed Inc., Vancouver, BC, Canada), and 2 × 10 6 treated cells injected into lethally irradiated CD45.1 mice and homed SKL cells analysed 16 h post-transplant. Homing of human CD34 + cells was evaluated in NSG mice. UCB mononuclear cells were pulsed with dmPGE 2 or vehicle and 4 × 10 7 cells transplanted into each of five sublethally irradiated (250 cGy) NSG mice. Homed CD34 + cells were analysed 16 h post-transplantation.
Analysis of CXCR4 expression and apoptosis
Mouse SKL cells or CD34 + UCB cells were pulsed with dmPGE 2 or vehicle, washed and cultured in RPMI-1640 ⁄ 10% HI-FBS at 37 °C for 24 h. CXCR4 expression was analysed using CXCR4-PE. Apoptotic levels were measured with FITC-annexin-V or FITC-antiactive caspase-3 after culture in RPMI-1640 ⁄ 2% HI-FBS at 37 °C for 24 h. For survivin and active caspase-3 detection, cells were permeabilized and fixed using the CytoFix ⁄ CytoPerm kit (BD Biosciences) and stained with anti-active caspase-3-FITC Flow Kit (BD Biosciences) or survivin-PE (R&D Systems, Minneapolis, MN, USA).
Survivin and active caspase-3
Mouse SKL cells or CD34 + UCB cells were pulsed with dmPGE 2 or vehicle, washed and cultured in RPMI-1640 ⁄ 10% HI-FBS at 37 °C for 24 h. CXCR4, survivin and ⁄ or active caspase-3 were analysed by FACS.
Migration assays
Chemotaxis to SDF-1a in vitro was determined as described previously (27) . Briefly, dmPGE 2 -and vehicle-treated Lineage neg bone marrow cells, UCB CD34 + cells or peripheral blood CD34 + cells mobilized by G-CSF were cultured in RPMI ⁄ 10% HI-FBS overnight, washed, 2 × 10 5 cells added to the top chamber of transwells, with or without rmSDF-1α (R&D Systems) in the bottom chamber, and incubated for 4 h at 37 °C. Cells migrating to the bottom chamber were enumerated by FACS. Per cent migration was calculated by dividing total cells migrated to lower well, by cell input, multiplied by 100.
Cell cycle analysis
Lineage neg cells were treated with dmPGE 2 or vehicle and cultured with rmSCF (50 ng ⁄ ml) (R&D Systems), rhFlt-3 and rhTPO (100 ng ⁄ ml each) (Immunex, Seattle, WA, USA) for 20 h. Cells were stained for SLAM SKL, fixed, permeabilized and stained with Hoechst-33342 followed by Pyronin-Y. Proportion of SLAM SKL cells in G 0 , G 1 , S and G 2 ⁄ M phase was determined by FACS.
Statistical analysis
All pooled values are expressed as mean ± SEM. Statistical differences were determined using paired or unpaired two-tailed t-test functions with Microsoft Excel as appropriate.
Results
PGE 2 increased long-term stem cell engraftment
Competitive repopulation transplantation models in mice allow for quantification of the ability of HSC to repopulate haematopoiesis. When congenic CD45.1 and CD45.2 mouse marrow cells were pulsed with vehicle or PGE 2 and transplanted in a limiting-dilution fashion, into CD45.1 ⁄ CD45.2 hybrid mice, a model that permits head-to-head comparison of HSC populations; significantly enhanced HSC engraftment was observed for PGE 2pulsed bone marrow, compared to controls (Table 1) . At 5 months post-transplantation, analysis of peripheral blood chimaerism showed significantly higher levels of white blood cells derived from PGE 2 -treated marrow cells. Analysis of HSC frequency by Poisson statistics or by calculation of competitive repopulating units (CRU), indicated an ~4-fold increase in HSC frequency, strongly suggesting a direct effect on HSC. These results agree with similar studies performed in a conventional congenic transplant model (26) . Myeloid cells, B and T lymphocytes were reconstituted with no obvious bias in lineage reconstitution. To validate self-renewal capacity of ex vivo PGE 2 -treated repopulating cells, marrow from primary transplantation recipients was harvested and transplanted into secondary recipients without any further ex vivo manipulation. Analysis of chimaerism at 24 weeks after secondary transplantation also showed significantly increased contribution to chimaerism from PGE 2 -treated cells from primary recipients ( Table 1) . That enhanced chimaerism resulting from PGE 2 exposure in primary donors was maintained in secondary transplants without additional treatment, indicated that the effect of PGE 2 pulse exposure was stable and manifest in long-term repopulating stem cells (LT-HSC). On further serial trans-plantation, persistent enhanced chimaerism resulting from PGE 2 pulse exposure prior to transplantation into primary donors, was observed. Transplantation of human haematopoietic cells in immunodeficient mice offers a model system to evaluate human HSC function in vivo (28) . In a similar fashion to that shown using mouse bone marrow cells, short-term ex vivo pulse exposure to PGE 2 enhanced engraftment of human UCB HSC in NOD ⁄ SCID-IL2-γ-receptor null (NSG) mice ( Table 1) .
PGE 2 increased HSC homing efficiency
Effects on cell division, homing or proliferation can positively or negatively affect HSC function. As we have previously shown that PGE 2 can have dual effects on haematopoiesis, we sought to define its mechanism of action to better understand the potential clinical utility of transient ex vivo PGE 2 exposure. Successful haematopoietic reconstitution requires that administered haematopoietic cells traffic ⁄ home to bone marrow niches where they can engraft, self-renew and differentiate. We therefore evaluated effects of PGE 2 exposure on these HSC functions.
To evaluate homing efficiency of HSC and determine whether the effect of PGE 2 pulse exposure results from direct PGE 2 effect, or is mediated through accessory cells, we FACS sorted congenic mouse Lineage neg Sca-1 + , c-kit + (SKL) cells, enriched for LT-HSC, treated them ex vivo and directly compared homing efficiency of PGE 2 -treated and vehicle-treated SKL cells head-to-head in CD45 hybrid mice. Pulse exposure of purified SKL cells to PGE 2 increased their homing efficiency 2-fold compared to controls ( Fig. 2a ). In traditional homing assays, increased homing of more differentiated Lineage neg , c-kit + HPC and Lineage neg cells was not observed, suggesting that the enhanced homing effect of PGE 2 is specific to HSC.
The CXCR4 and SDF-1a axis is a critical component of HSC marrow homing (29) , and overexpression of CXCR4 in HSC enhances their in vivo homing and engraftment (30) (31) (32) .
To determine whether up-regulated CXCR4 would mediate PGE 2 -enhanced HSC marrow homing, marrow cells were treated ex vivo with selective CXCR4 antagonist AMD3100 (33) after PGE 2 pulse exposure and prior to transplantation (Fig. 2b) . As expected, PGE 2 pulse exposure increased SKL cell homing. Incubation of vehicle or PGE 2 -pulsed cells with AMD3100 reduced SKL cell homing and abrogated PGE 2 -improved homing efficiency. Reduction in HSC homing by AMD3100 is consistent with previous reports (34, 35) . To verify the enhancing effect of PGE 2 on human cells, CD34 + cells were isolated from cord blood, pulsed with PGE 2 or vehicle and their homing capacity analysed in NSG mice, a validated model for human HSC homing (36) . PGE 2 pulse exposure significantly enhanced homing efficiency of human UCB CD34 + cells in NSG mice (Fig. 2c) .
PGE 2 increased HSC CXCR4 and migration to SDF-1α
As PGE 2 enhancement of HSC homing was blocked by CXCR4 antagonism and PGE 2 has been reported to upregulate CXCR4 on CD34 + cells (37) and endothelial cells (38) , and increase monocyte chemotaxis to SDF-1α (39), we evaluated whether improved homing would result from HSC up-regulation of SDF-1α⁄ CXCR4 signalling and function. Pulse exposure to PGE 2 increased CXCR4 expression on mouse SKL cells and human UCB CD34 + cells ( Table 2 ). HSC selectively migrate to SDF-1α in vitro (40) , a process that reflects their in vivo homing capacity. Vehicle-and PGE 2 -treated mouse SKL cells and CD34 + cells from human UCB and G-CSF mobilized peripheral blood all demonstrated significant migration to 100 ng ⁄ ml SDF-1α; however, in all cases, chemotaxis of PGE 2treated cells was significantly higher ( Table 2) , indicating that up-regulation of HSC CXCR4 coincided with enhanced migratory funct ion. The enhancing effect of PGE 2 on chemotaxis to SDF-1α was blocked by AMD3100, indicating that the observed effect was mediated through the CXCR4 receptor.
PGE 2 decreased apoptosis
Apoptosis is an important regulatory process in normal and malignant haematopoiesis and signalling downstream of PGE 2 receptors has been implicated in anti-apoptotic effects (41) (42) (43) . This suggests that enhancement of HSC function by PGE 2 could result from enhanced HSC survival. Under reduced serum conditions, pulse exposure to PGE 2 reduced annexin-V and active caspase-3 in SKL cells, markers of apoptosis in mouse and human HSC (Fig.  3a,b ). Furthermore, intracellular levels of the endogenous caspase-3 inhibitor survivin, were significantly higher in both SKL and CD34 + cells, consistent with our previous findings that survivin regulated apoptosis and proliferation in HSC (44, 45) , and studies by others that PGE 2 can increase survivin levels in cancer cells (46, 47) . QRT-PCR analysis of treated SKL cells and UCB CD34 + cells showed similarly elevated levels of survivin mRNA.
PGE 2 increased entry of HSC into the cell cycle
We have previously shown that survivin regulates entry of HSC into the cell cycle and their progression through it (44, 45) . Furthermore, β-catenin, which is implicated in HSC proliferation ⁄ self-renewal, lies downstream of EP receptor pathways (48) . Ability of PGE 2 to modulate these cell cycle regulators suggests that increase in HSC self-renewal and proliferation might contribute to enhanced engraftment observed using PGE 2 -pulsed cells. PGE 2 pulse exposure significantly increased the proportion of primitive LT-HSC, defined as SLAM (CD150 + , CD48 -) SKL cells, in the cell cycle (G 1 + S ⁄ G 2 M) compared to controls (Fig. 4) . No significant effect on rate of cell cycle completion by HPC or more differentiated cells, was observed (data not shown), strongly suggesting that effects of PGE 2 on cell cycle rate were selective.
Discussion
In vivo analysis of effects of short-term pulse exposure to PGE 2 clearly demonstrated that it has direct and stable effects on HSC function. Enhancement of HSC frequency and engraftment by PGE 2 treatment results from effects on HSC homing and cell cycle activity involving up-regulation of CXCR4 and survivin, with increased chemotactic response to SDF-1α and reduced apoptosis. Ability to facilitate homing, survival and proliferation of HSC by short-term ex vivo PGE 2 exposure offers an exciting clinical translation strategy to improve haematopoietic transplantation, specially in transplant settings characterized by low HSC numbers, such as with umbilical cord blood cells and some mobilized peripheral blood stem cell products. Our experimental pre-clinical limiting dilution transplantation studies show that equivalent engraftment is achieved with 4-fold fewer PGE 2 -treated cells compared to untreated cells. Homing and migration studies utilizing UCB CD34 + cells also clearly support potential translation of short-term PGE 2 exposure to human haematopoietic grafts.
While ex vivo utility of PGE 2 is clear, it will be interesting to determine whether enhanced HSC engraftment ⁄ recovery could also be achieved by administering PGE 2 in vivo or if PGE 2 used in vivo could further facilitate engraftment of HSC exposed to PGE 2 ex vivo. In COX2 knockout mice, haematopoietic recovery from chemotherapy is delayed (49) suggesting that PGE 2 production is critical for HSC expansion. However, it must be kept in mind that while short-term exposure to PGE 2 can enhance HSC function, prolonged administration inhibits myelopoiesis (11, 50) , which is supported by inhibition of prostaglandin biosynthesis in vivo leading to expansion of myelopoiesis (51) , at least in mice. Nevertheless, combination of transient ex vivo PGE 2 exposure with selective modulation of in vivo PGE 2 biosynthesis may result in significant further improvements in HSC function. c CRU were calculated based on PB chimaerism at 20 weeks in primary transplants according to the method of Harrison (24) .
d Chimaerism in PB is shown at 20 weeks in primary transplant and 24 weeks in secondary transplant (mean ± SEM). Data are for 10 mice in two experiments, each assayed individually.
